Reyataz label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: Potential for increased levels of grazoprevir
Drug 1
Drug 2
Drug 2 dose
Elbasvir 50 mg daily with grazoprevir 200 mg daily
Drug 2 effect
Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold
Clinical Effects
May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition
Management
Contraindicated. Use alternative agents.
Import ID
824
